UNIVERSITY OF ALABAMA AT BIRMINGHAM

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1969-01-01

Employees: 2K

Market Cap: -

Website: http://www.uab.edu

Clinical Trials

A Study for Testing Text Messaging and Newsletter as a Strategy for Interrupting Sedentary Behavior

Not Applicable

Completed

Conditions: Multiple Sclerosis

Interventions: Behavioral: Social Cognitive Theory based text messages

First Posted Date: 2018-09-14

Last Posted Date: 2019-11-29

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 30

Registration Number: NCT03671499

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States

Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care

Phase 4

Active, not recruiting

Conditions: HIV
Smoking Cessation
AIDS

Interventions: Drug: Algorithm Treatment
Other: Quitline only

First Posted Date: 2018-09-13

Last Posted Date: 2025-06-09

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 600

Registration Number: NCT03670316

Locations: 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States

Prevention Through Intervention: Telehealth Solution to Deter 911 Calls Due to Hypoglycemia

Not Applicable

Completed

Conditions: Diabetes Mellitus
Hypoglycemia Unawareness
Hypoglycemia
Hypoglycemia Acute

Interventions: Behavioral: Hypoglycemia Education

First Posted Date: 2018-09-11

Last Posted Date: 2020-07-22

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 50

Registration Number: NCT03665870

Locations: 🇺🇸
Birmingham Fire and Rescue Service, Birmingham, Alabama, United States

Trial of C134 in Patients With Recurrent GBM

Phase 1

Active, not recruiting

Conditions: Glioblastoma Multiforme of Brain
Anaplastic Astrocytoma of Brain
Gliosarcoma of Brain

Interventions: Biological: C134

First Posted Date: 2018-09-05

Last Posted Date: 2024-08-22

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 19

Registration Number: NCT03657576

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus Intrathecal Morphine Alone

Early Phase 1

Terminated

Conditions: Gynecologic Cancer

Interventions: Drug: Lidocaine Bolus Infusion
Procedure: QL block
Drug: Saline Bolus Infusion
Procedure: Simulated QL block

First Posted Date: 2018-09-05

Last Posted Date: 2021-05-10

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 1

Registration Number: NCT03658109

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: [68Ga]DOTATATE-PET/MRI

First Posted Date: 2018-08-27

Last Posted Date: 2023-01-10

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 12

Registration Number: NCT03648073

Locations: 🇺🇸
University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States

RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Radiation: 5 Fraction Stereotactic Body Radiation Therapy

First Posted Date: 2018-08-23

Last Posted Date: 2025-03-10

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 40

Registration Number: NCT03643861

Locations: 🇺🇸
University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, Alabama, United States

Tuberculosis Diagnosis by Flow Cytometry

Withdrawn

Conditions: Tuberculosis

First Posted Date: 2018-08-20

Last Posted Date: 2018-11-20

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT03639038

Locations: 🇿🇲
Center for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia

Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations

Phase 4

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: Symdeko
Drug: Ivacaftor and Symdeko

First Posted Date: 2018-08-09

Last Posted Date: 2025-04-16

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 1

Registration Number: NCT03624101

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers

Early Phase 1

Withdrawn

Conditions: Neuroendocrine Carcinoma of Pancreas
Carcinoid

Interventions: Drug: Gallium Dotatate

First Posted Date: 2018-08-09

Last Posted Date: 2023-09-11

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT03623984

Locations: 🇺🇸
UAB Kirklin Clinic, Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy